Skip to main content
Top
Published in: International Journal of Hematology 1/2017

01-07-2017 | Original Article

Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE)

Authors: Inaam Bashir Hassan, Mariam R. Al Zaabi, Arif Alam, Mohammed Jawad Hashim, Martin S. Tallman, Jorgen Kristensen

Published in: International Journal of Hematology | Issue 1/2017

Login to get access

Abstract

Although acute promyelocytic leukemia (APL) is a curable hematologic malignancy, early death (ED) remains a significant cause of treatment failure especially in developing countries. In a retrospective data analysis of 67 adult APL patients diagnosed in United Arab Emirates we report an ED rate of 11.9% which is comparable to that reported from more developed countries. We identified the following parameters at presentation as significant predictor of increased ED: Age >40 years (P = 0.015), fever (P = 0.030), WBC count >20 × 109/L (P = 0.010), the breakpoints other than bcr1 (P = 0.043) and fibrinogen level <1.5 g/L (P = 0.025). Delay in ATRA administration beyond 24 h from admission and fibrinogen <150 mg/dL were also significant predictors of ED, but only among high-risk patients (P = 0.035 and P = 0.033, respectively). WBC count >10 × 109/L and expression of HLA-DR (P = 0.018) or CD2 (P = 0.017) were significant predictors for differentiation syndrome (DS) which was found to be a predictor of ED (P = 0.002). Reducing the APL related ED rate in centers with limited resources is feasible provided early initiation of ATRA administration and early correction of coagulopathy in high-risk patients in addition to prompt treatment of DS. To our knowledge this is the first report from the Arabian Gulf describing ED in APL.
Literature
1.
go back to reference Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.CrossRefPubMed Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8.CrossRefPubMed
2.
go back to reference Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol. 1980;44:169–70.CrossRefPubMed Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol. 1980;44:169–70.CrossRefPubMed
3.
go back to reference Orfao A, Chillón MC, Bortoluci AM, López-Berges MC, García-Sanz R, Gonzalez M, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukaemia is highly characteristic of the presence of PML-RARα gene rearrangements. Haematologica. 1999;84:405–12.PubMed Orfao A, Chillón MC, Bortoluci AM, López-Berges MC, García-Sanz R, Gonzalez M, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukaemia is highly characteristic of the presence of PML-RARα gene rearrangements. Haematologica. 1999;84:405–12.PubMed
4.
go back to reference Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:369–85.CrossRefPubMed Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:369–85.CrossRefPubMed
5.
go back to reference Cullen MJ, Richards SJ, O’Connor SJ, Dickinson H, Sharpe C, Swirsky DM, et al. Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. Cancer Genet Cytogenet. 2004;148:176–7.CrossRefPubMed Cullen MJ, Richards SJ, O’Connor SJ, Dickinson H, Sharpe C, Swirsky DM, et al. Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. Cancer Genet Cytogenet. 2004;148:176–7.CrossRefPubMed
6.
go back to reference Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med. 1984;76:827–41.CrossRefPubMed Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med. 1984;76:827–41.CrossRefPubMed
7.
go back to reference de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675–84.CrossRefPubMed de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675–84.CrossRefPubMed
8.
go back to reference Han J-Y, Kim K-E, Kim K-H, Park J-I, Kim J-S. Identification of PML–RARA rearrangement by RT-PCR and sequencing in an acute promyelocytic leukemia without t(15;17) on G-banding and FISH. Leuk Res. 2007;31:239–43.CrossRefPubMed Han J-Y, Kim K-E, Kim K-H, Park J-I, Kim J-S. Identification of PML–RARA rearrangement by RT-PCR and sequencing in an acute promyelocytic leukemia without t(15;17) on G-banding and FISH. Leuk Res. 2007;31:239–43.CrossRefPubMed
9.
go back to reference Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Practice & Research Clinical Haematology. 2014;27:3–9.CrossRef Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Practice & Research Clinical Haematology. 2014;27:3–9.CrossRef
10.
go back to reference Reiter A, Saussele S, Grimwade D, Wiemels JL, Segal MR, Lafage-Pochitaloff M, et al. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromos Cancer. 2003;36:175–88.CrossRefPubMed Reiter A, Saussele S, Grimwade D, Wiemels JL, Segal MR, Lafage-Pochitaloff M, et al. Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromos Cancer. 2003;36:175–88.CrossRefPubMed
11.
go back to reference Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875–91.CrossRefPubMed Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875–91.CrossRefPubMed
12.
13.
go back to reference Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood. 2005;105(8):3019–25.CrossRefPubMed Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood. 2005;105(8):3019–25.CrossRefPubMed
14.
go back to reference Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia, The European APL Group. Blood. 1999;94(4):1192–200.PubMed Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia, The European APL Group. Blood. 1999;94(4):1192–200.PubMed
15.
go back to reference Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115:5137–46.CrossRefPubMed Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115:5137–46.CrossRefPubMed
16.
go back to reference Huang H, Qin Y, Xu R, You X, Teng R, Yang L, Xu M, Liu H. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leuk Res. 2012;36(7):841–5.CrossRefPubMed Huang H, Qin Y, Xu R, You X, Teng R, Yang L, Xu M, Liu H. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leuk Res. 2012;36(7):841–5.CrossRefPubMed
17.
go back to reference Ades L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, et al. European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with alltrans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115(9):1690–6.CrossRefPubMed Ades L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, et al. European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with alltrans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010;115(9):1690–6.CrossRefPubMed
18.
go back to reference Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, et al. GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716–25.CrossRefPubMed Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, et al. GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716–25.CrossRefPubMed
19.
go back to reference Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171–9.CrossRefPubMed Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A, et al. Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010;116(17):3171–9.CrossRefPubMed
20.
go back to reference Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751–7.CrossRefPubMedPubMedCentral Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751–7.CrossRefPubMedPubMedCentral
21.
go back to reference Tallman MS, Manji GA. Don’t just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary. Blood Cells Mol Dis. 2011;46(2):173–4.CrossRefPubMed Tallman MS, Manji GA. Don’t just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary. Blood Cells Mol Dis. 2011;46(2):173–4.CrossRefPubMed
22.
go back to reference Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128–34.CrossRefPubMed Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128–34.CrossRefPubMed
23.
go back to reference Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013. Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013.
24.
go back to reference Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013;121(11):1935–43.CrossRefPubMed Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013;121(11):1935–43.CrossRefPubMed
25.
go back to reference Park JH, Qiao BZ, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–54.CrossRefPubMedPubMedCentral Park JH, Qiao BZ, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–54.CrossRefPubMedPubMedCentral
26.
go back to reference Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111(3):1078–84.CrossRefPubMed Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111(3):1078–84.CrossRefPubMed
27.
go back to reference Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78(3):213–9.CrossRefPubMed Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78(3):213–9.CrossRefPubMed
28.
go back to reference de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395–402.CrossRefPubMed de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395–402.CrossRefPubMed
29.
go back to reference Pagoni M, Garofalaki M, Panitsas F, Manola K, Psarra K, Economopoulos P, et al. Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis. 2011;3:e2011053.CrossRefPubMedPubMedCentral Pagoni M, Garofalaki M, Panitsas F, Manola K, Psarra K, Economopoulos P, et al. Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis. 2011;3:e2011053.CrossRefPubMedPubMedCentral
30.
go back to reference Rashidi A, Riley M, Goldin TA, Sayedian F, Bayerl MG, Aguilera NS, et al. Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United States. Leuk Res. 2014;38:1036–40.CrossRefPubMed Rashidi A, Riley M, Goldin TA, Sayedian F, Bayerl MG, Aguilera NS, et al. Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United States. Leuk Res. 2014;38:1036–40.CrossRefPubMed
31.
go back to reference Lengfelder E, Hofmann WK, Nolte F. Management of elderly patients with acute promyelocytic leukemia: progress and problems. Ann Hematol. 2013;92(9):1181–8.CrossRefPubMedPubMedCentral Lengfelder E, Hofmann WK, Nolte F. Management of elderly patients with acute promyelocytic leukemia: progress and problems. Ann Hematol. 2013;92(9):1181–8.CrossRefPubMedPubMedCentral
32.
go back to reference Jácomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92(10):1431–2.CrossRefPubMed Jácomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92(10):1431–2.CrossRefPubMed
33.
go back to reference Jeddi R, Ghédira H, Ben Amor R, et al. Treatment of Acute Promyelocytic Leukemia with AIDA Based Regimen. Update of a Tunisian Single Center Study. Mediterr J Hematol. Infect Dis. 2011;3(1):e2011033. Jeddi R, Ghédira H, Ben Amor R, et al. Treatment of Acute Promyelocytic Leukemia with AIDA Based Regimen. Update of a Tunisian Single Center Study. Mediterr J Hematol. Infect Dis. 2011;3(1):e2011033.
34.
go back to reference Karim F, Shaikh U, Adil SN, Khurshid M. Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre. Singapore Med J. 2014;55(8):443–7.CrossRefPubMedPubMedCentral Karim F, Shaikh U, Adil SN, Khurshid M. Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre. Singapore Med J. 2014;55(8):443–7.CrossRefPubMedPubMedCentral
35.
go back to reference Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program. 2006:162–8. Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program. 2006:162–8.
36.
go back to reference Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–53.PubMed Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247–53.PubMed
37.
go back to reference Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood. 1996;88(4):1390–8.PubMed Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, Lazzarino M, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood. 1996;88(4):1390–8.PubMed
38.
go back to reference Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med. 1992;117(4):292–6.CrossRefPubMed Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med. 1992;117(4):292–6.CrossRefPubMed
39.
go back to reference Khorshid O, Diaa A, Moaty MA, Fatah RA, Dessouki IE, Hamid MA, et al. Clinical Features and Treatment Outcome of Patients Treated at Cairo National Cancer Institute in Egypt. Mediterr J Hematol Infect Dis 201;3(1). Khorshid O, Diaa A, Moaty MA, Fatah RA, Dessouki IE, Hamid MA, et al. Clinical Features and Treatment Outcome of Patients Treated at Cairo National Cancer Institute in Egypt. Mediterr J Hematol Infect Dis 201;3(1).
40.
go back to reference Yildirim R, Gundogdu M, Ozbıcer A, Kiki I, Erdem F, Dogan H. Acute promyelocytic leukemia, centre, experience. Turkey. Transfusion and Apheresis Science. 2013;48:45–9.CrossRefPubMed Yildirim R, Gundogdu M, Ozbıcer A, Kiki I, Erdem F, Dogan H. Acute promyelocytic leukemia, centre, experience. Turkey. Transfusion and Apheresis Science. 2013;48:45–9.CrossRefPubMed
41.
go back to reference McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97:133–6.CrossRefPubMedPubMedCentral McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97:133–6.CrossRefPubMedPubMedCentral
42.
go back to reference Mitrovic M, Suvajdzic N, Bogdanovic A, Kurtovic NK, Sretenovic A, Elezovic I, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol. 2013;30(1):47.CrossRef Mitrovic M, Suvajdzic N, Bogdanovic A, Kurtovic NK, Sretenovic A, Elezovic I, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol. 2013;30(1):47.CrossRef
43.
go back to reference Chatterjee T, Gupta S, Sharma S, Ganguli P. Distribution of different PML/RARα bcr isoforms in Indian Acute Promyelocytic Leukemia (APL) patients and clinicohematological correlation. Mediterr J Hematol Infect Dis. 2014;6(1):e2014004.CrossRefPubMedPubMedCentral Chatterjee T, Gupta S, Sharma S, Ganguli P. Distribution of different PML/RARα bcr isoforms in Indian Acute Promyelocytic Leukemia (APL) patients and clinicohematological correlation. Mediterr J Hematol Infect Dis. 2014;6(1):e2014004.CrossRefPubMedPubMedCentral
44.
go back to reference Gonzalez M, Barragan E, Bolufer P, Chillón C, Colomer D, Borstein R, et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to PML-RARA isoforms: a study of PETHEMA group. Br J Haematol. 2001;114:99–103.CrossRefPubMed Gonzalez M, Barragan E, Bolufer P, Chillón C, Colomer D, Borstein R, et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to PML-RARA isoforms: a study of PETHEMA group. Br J Haematol. 2001;114:99–103.CrossRefPubMed
45.
go back to reference De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801–6.PubMed De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801–6.PubMed
46.
go back to reference Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010;95(3):424–31.CrossRefPubMed Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010;95(3):424–31.CrossRefPubMed
47.
go back to reference Lou Y, Suo S, Tong H, Ye X, Ye X, Wang Y, Chen Z, et al. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy Leuk Res. 2013;37(11):1451–6.PubMed Lou Y, Suo S, Tong H, Ye X, Ye X, Wang Y, Chen Z, et al. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy Leuk Res. 2013;37(11):1451–6.PubMed
48.
go back to reference Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–83.CrossRefPubMed Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–83.CrossRefPubMed
49.
go back to reference Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998;16(1):78–85.CrossRefPubMed Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998;16(1):78–85.CrossRefPubMed
50.
go back to reference De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92(8):2712–8.PubMed De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92(8):2712–8.PubMed
51.
go back to reference Tallman MS, Andersen JW, Schiffer CA, Frederick R, Appelbaum FR, Feusner JH, Ogden A, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95(1):90–5.PubMed Tallman MS, Andersen JW, Schiffer CA, Frederick R, Appelbaum FR, Feusner JH, Ogden A, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95(1):90–5.PubMed
52.
go back to reference Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994;84(11):3843–9.PubMed Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood. 1994;84(11):3843–9.PubMed
53.
go back to reference Cunha De Santis G, Tamarozzi MB, Sousa RB, Moreno SE, Moreno SE, Secco D, Garcia AB, et al. Adhesion molecules and Differentiation Syndrome: phenotypic and. functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica. 2007;92(12):1615–22.CrossRefPubMed Cunha De Santis G, Tamarozzi MB, Sousa RB, Moreno SE, Moreno SE, Secco D, Garcia AB, et al. Adhesion molecules and Differentiation Syndrome: phenotypic and. functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica. 2007;92(12):1615–22.CrossRefPubMed
Metadata
Title
Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE)
Authors
Inaam Bashir Hassan
Mariam R. Al Zaabi
Arif Alam
Mohammed Jawad Hashim
Martin S. Tallman
Jorgen Kristensen
Publication date
01-07-2017
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2211-7

Other articles of this Issue 1/2017

International Journal of Hematology 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine